Targeting Sclerostin in Postmenopausal Osteoporosis: Focus on Romosozumab and Blosozumab

Show simple item record Reid, Ian en 2017-08-10T01:17:06Z en 2017-08 en
dc.identifier.citation BioDrugs 31(4):289-297 Aug 2017 en
dc.identifier.issn 1173-8804 en
dc.identifier.uri en
dc.description.abstract Most current treatments for osteoporosis inhibit bone resorption and reduce total fracture numbers by about one-quarter. The identification of the osteocytic protein sclerostin as a potent regulator of bone turnover and bone density has led to the development of a new therapeutic class-agents that inhibit sclerostin activity, resulting in increased bone formation and reduced bone resorption. Romosozumab and blosozumab are monoclonal antibodies that bind to sclerostin, reducing its inhibition of Wnt signaling. They have comparable activities in phase I and II studies, doubling formation markers, halving resorption indices, and increasing spine bone density by >10% over 12 months. Only romosozumab has progressed to phase III, where the first study showed a 73% reduction in vertebral fracture risk and a 36% reduction in clinical fractures at 1 year. It was well-tolerated. A further phase III study will conclude in 2017. Romosozumab is a very promising medication in the management of established osteoporosis, but much remains to be done to determine its optimal duration and sequence of administration. en
dc.format.medium Print-Electronic en
dc.language eng en
dc.publisher Adis International Ltd. en
dc.relation.ispartofseries BioDrugs en
dc.rights Items in ResearchSpace are protected by copyright, with all rights reserved, unless otherwise indicated. Previously published items are made available in accordance with the copyright policy of the publisher. en
dc.rights.uri en
dc.title Targeting Sclerostin in Postmenopausal Osteoporosis: Focus on Romosozumab and Blosozumab en
dc.type Journal Article en
dc.identifier.doi 10.1007/s40259-017-0229-2 en
pubs.issue 4 en
pubs.begin-page 289 en
pubs.volume 31 en
dc.rights.holder Copyright: Adis International Ltd. en
dc.identifier.pmid 28547661 en
pubs.end-page 297 en
dc.rights.accessrights en
pubs.subtype Article en
pubs.elements-id 627421 en Medical and Health Sciences en School of Medicine en Medicine Department en Science en Science Research en Maurice Wilkins Centre (2010-2014) en
dc.identifier.eissn 1179-190X en
pubs.record-created-at-source-date 2017-08-10 en 2017-05-25 en
pubs.dimensions-id 28547661 en

Files in this item

There are no files associated with this item.

Find Full text

This item appears in the following Collection(s)

Show simple item record


Search ResearchSpace